News Daily News Injectable Semaglutide Shortage Forces Physicians to Pivot Todd Neale February 05, 2024
News Daily News European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba Michael O'Riordan September 15, 2023
News ESC 2023 Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST Michael O'Riordan August 27, 2023
News Daily News SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity Todd Neale August 08, 2023
News Daily News SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients Todd Neale July 17, 2023
News Daily News Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval Michael O'Riordan March 03, 2021
News Daily News AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More Shelley Wood December 17, 2020
News Conference News EAS 2020 Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention Michael O'Riordan October 08, 2020
News Conference News ACC 2020 Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events Michael O'Riordan April 02, 2020
News Daily News Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis Caitlin E. Cox February 07, 2020
News Features Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019 Todd Neale December 10, 2019
News Conference News AHA 2019 Inclisiran in FH: Safe, Cuts LDL in This Challenging Group Yael L. Maxwell November 19, 2019
News Conference News AHA 2019 Inclisiran Slashes LDL in ASCVD Patients: ORION-10 Yael L. Maxwell November 16, 2019
News Conference News ESC 2019 ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date Yael L. Maxwell September 03, 2019
News Daily News CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX Michael O'Riordan July 30, 2019
News Conference News EAS 2019 Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION Michael O'Riordan June 04, 2019
News Features Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis? Michael O'Riordan February 01, 2019
News Conference News ESC 2018 Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR Shelley Wood August 28, 2018